| ²é¿´: 773 | »Ø¸´: 2 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
xydouble½ð³æ (³õÈëÎÄ̳)
|
[ÇóÖú]
¼¸¾ä»°µÄ·Ò룬ҽѧ·½ÃæµÄ
|
||
|
1.This is based on both the existing research evidence showing liver cyst growth effects of estrogen and the clinical observation of more symptomatic, rapid liver cyst growth and more frequent requirement of interventions associated with high-level estrogen exposure. £¨F:\¹ØÓÚ¸ÎÄÒÖ×\¶àÄÒ¸Î\Isolated+polycystic+liver+disease.PDF£© Õâ¸ö£¨associated with high-level estrogen exposure£©ÊÇÐÞÊÎ˵ÄÄØ£¿ÐèÀíÇå½á¹¹²¢·Òë¡£ 2.. In view of its stimulatory effects on cell proliferation and fluid secretion, a major approach has been to target cAMP production. £¨F:\¹ØÓÚ¸ÎÄÒÖ×\¶àÄÒ¸Î\polycystic liver disease.pdf£© £¨1£©·Ò룬£¨2£©has been to ÊǸöʲôÇé¿ö£¿»¹ÊÇapproach to ?²»¶® 3.Thus,autocrine/paracrine loops are established where these factors are secreted and accumulate within the cyst fluid ,bind to receptors and signal cell proliferation of the lining epithelium £¨C:\Users\ibm\Desktop\Õï¶Ï ÖÎÁƵÄ\Advances in management of polycystic liver disease.pdf£© £¨1£©whereÒýµ¼µÄÊǸö¶¨Óï´Ó¾äÂð£¿ÐÞÊÎËÄØloops Â𣬵«ÊÇÒâ˼Éϸоõ²»¶Ô°¡¡£ £¨2£©·Òë 4. The role of vasopressin action in modifying cyst expansion in ADPKD has been given added weight by recent studies which indirectly suppressed (high fluid intake) or enhanced its action (endothelin B receptor blockade)on the collecting duct. given added weightÔÚ±¾¾äÖÐÔõô·ÒëºÏÊÊ£¿ È«¾ä·Òë 5.The protein products of these genes (hepatocystin and Sec63, respectively) act in concert to achieve proper topology and folding of integral membrane or secreted glycoproteins in the endoplasmic reticulum (ER) £¨C:\Users\ibm\Desktop\Õï¶Ï ÖÎÁƵÄ\Medical and surgical treatment options for polycystic liver disease..pdf£© ·ÖÎöÒ»ÏÂÕâ¸ö¾ä×ӵĽṹ£¬ÎÒÖªµÀin concert toºóÃæÒýµ¼µÄÊDZöÓï´Ó¾ä£¨ÊDZöÓï°É£©ºóÃæÓм¸¸öÁ¬½Ó´Êand /or , ÄÇôÈçºÎÖªµÀÕâ¸öin the endoplasmic£¨ER)ÐÞÊεÄÄÄÒ»²¿·ÖÄØ£¬ÊÇor ǰºó£¬»¹Êǽö½öorºóÃæµÄÄØ£¿ ÔÙ·Òëһϣ¬Ð»Ð» 6. One of the potential factors in promoting cyst growth is cAMP.Secretin, the major cAMP agonist in cholangiocytes, stimulates the targeting and insertion of several transporters and channels into the apical membrane of cholangiocytes. £¨C:\Users\ibm\Desktop\Õï¶Ï ÖÎÁƵÄ\Medical and surgical treatment options for polycystic liver disease..pdf£© Õâ¸öpotential factors£¬Ôõô·Òë×î±ê׼Ĩ£¿×îºóÒ»¾äÒ²²»¶®£¬¼´ stimulatesÖÁ×îºó£¬¸Ð¾õ²»Í¨ÄØ£¿ ÎҵĽð±Ò²»ÊǺܶ࣬ËùÒÔÓеãÉá²»µÃ¸ø£¬ºÙºÙ£¬ÐüÉÍÓеãÉÙ£¬Èç¹ûÄܵõ½´ó¼Ò°ïÖú£¬·Ç³£¸Ðл£¡ |
» ²ÂÄãϲ»¶
317Çóµ÷¼Á
ÒѾÓÐ18È˻ظ´
293Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
280·ÖÇóµ÷¼Á Ò»Ö¾Ô¸085802
ÒѾÓÐ7È˻ظ´
0854µç×ÓÐÅÏ¢Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
263Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
ʯºÓ×Ó´óѧ£¨211¡¢Ë«Ò»Á÷£©Ë¶²©Ñо¿Éú³¤ÆÚÕÐÉú¹«¸æ
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸Î÷°²½»Í¨´óѧ²ÄÁϹ¤³Ìרҵ 282·ÖÇóµ÷¼Á
ÒѾÓÐ13È˻ظ´
±±¿Æ281ѧ˶²ÄÁÏÇóµ÷¼Á
ÒѾÓÐ6È˻ظ´
328Çóµ÷¼Á£¬Ó¢ÓïÁù¼¶551£¬ÓпÆÑоÀú
ÒѾÓÐ10È˻ظ´
298Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
Ѿµ°¶ù¸ñ¸ñ
Òø³æ (СÓÐÃûÆø)
- ·ÒëEPI: 16
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 394.3
- ºì»¨: 4
- Ìû×Ó: 120
- ÔÚÏß: 32.5Сʱ
- ³æºÅ: 1298622
- ×¢²á: 2011-05-17
- ÐÔ±ð: MM
- רҵ: Íâ¹úÓïÑÔ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï
sltmac(½ð±Ò+1): лл½»Á÷~~ 2011-06-05 19:15:06
xydouble(½ð±Ò+5): ÓÐЩ·ÒëµÄ²»¶Ô 2011-06-06 16:43:56
sltmac(½ð±Ò+1): лл½»Á÷~~ 2011-06-05 19:15:06
xydouble(½ð±Ò+5): ÓÐЩ·ÒëµÄ²»¶Ô 2011-06-06 16:43:56
|
1.¸ù¾ÝÏÖÓÐÑо¿ÏÔʾ¸ÎÄÒÖ×À©É¢´ÆÐÔ¼¤ËØÒÔ¼°ÒÀ¾Ý½Ï¶àÁÙ´²Ö¢×´¹Û²ì£¬Ëæ×ŸÎÄÒÖ×µÄѸËÙÀ©É¢ÐèÒª¸ü×¢Èë¸ßˮƽµÄ´ÆÐÔ¼¤Ëر©Â¶µÄ´ÎÊý»á¸ü¶à¡£ 2.ÓÉÓÚ»·ÏÙÜÕËá¶Ôϸ°ûÔöÉú¼°Á÷Ìå·ÖÃÚÎïÆð´Ì¼¤×÷Óã¬Òò´Ë³ÉÎªÖÆÈ¡»·ÏÙÜÕËáµÄÖ÷Òª·½·¨ 3.Òò´Ë£¬·ÖÃÚ³öµÄ¸÷ÖÖÒò×ÓÔÚÄÒÄÚÒº»ýÀÛ£¬ÓëÊÜÌå½áºÏ ÔÚÉñ¾Ä©ÉÒÉÏ²ã½øÐе¥Ï¸°ûÔöÖ³£¬¼´²úÉúÁË×Ô·ÖÃÚ/ÅÔ·ÖÃÚÑ»·¡£ 4.½ü¼¸Ä꿹ÀûÄò¼¤ËØÔÚADPKDÖÐÒÖÖÆÄÒÖ×À©É¢Ê±ËùÆðµÄ×÷Óõõ½ÖØÊÓ£¬¿¹ÀûÄò¼¤ËØ¿ÉÒÔ¼ä½ÓµØÒÖÖÆ£¨¸ßÉãÈëÁ¿£©»ò¼ÓÇ¿ÔÚ¼¯Äò¹ÜÖеÄ×÷Óã¨ÄÚÆ¤BÊÜÌåµÄ×èÖÍ£© 5.ÕâЩ»ùÒò²úÉúµÄµ°°×ÖʲúÆ·£¨·Ö±ðΪ(hepatocystinºÍ Sec63£©¿ÉÓÃ×÷·ûºÏÒªÇóµÄ±íÃæ½á¹¹¼°¿ÉÕÛµþµÄÍêÕûµÄ±¡Ä¤£¬»òÊÇÔÚÄÚÖÊÍøÄÚ·ÖÃÚõ±µ°°×ÖÊ 6.´Ù½øÄÒÖ×À©É¢µÄDZÔÚÔÒòÖ®Ò»¼´»·ÏÙÜÕËá·ÖÃÚËØ£¬ËüÊǵ¨¹Üϸ°ûÖл·ÏÙÜÕËáµÄ¼¤¶¯¼Á£¬´Ì¼¤µ¨¹Üϸ°ûÖÐÁ¬½Óµ½¶¥Ä¤µÄһЩÔËÊä×éÖ¯ºÍµ¼¹Ü¡£ |

2Â¥2011-06-04 21:25:30
8814402
ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 509
- Ó¦Öú: 18 (СѧÉú)
- ¹ó±ö: 0.381
- ½ð±Ò: 12916.1
- É¢½ð: 47
- ºì»¨: 16
- Ìû×Ó: 4183
- ÔÚÏß: 357.8Сʱ
- ³æºÅ: 1184404
- ×¢²á: 2011-01-06
- רҵ: Ò©ÎïѧÆäËû¿ÆÑ§ÎÊÌâ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï
sltmac(½ð±Ò+1): лл½»Á÷~~ 2011-06-05 19:15:13
xydouble(½ð±Ò+5, ·ÒëEPI+1): ÆäʵÎÒ»¹ÊÇÐèҪһϷÒëµÄ¡£Äã˵µÄ¶Ô£¬ÎªÁË֪ʶ£¬ÊDz»Ó¦¸ÃÁߨ쬵«ÎÒ¾õµÃÎÒÓÐÕâÖÖСÏë·¨£¬Ò²ÊÇÈËÖ®³£ÇéµÄ 2011-06-05 22:11:14
sltmac(½ð±Ò+1): лл½»Á÷~~ 2011-06-05 19:15:13
xydouble(½ð±Ò+5, ·ÒëEPI+1): ÆäʵÎÒ»¹ÊÇÐèҪһϷÒëµÄ¡£Äã˵µÄ¶Ô£¬ÎªÁË֪ʶ£¬ÊDz»Ó¦¸ÃÁߨ쬵«ÎÒ¾õµÃÎÒÓÐÕâÖÖСÏë·¨£¬Ò²ÊÇÈËÖ®³£ÇéµÄ 2011-06-05 22:11:14
|
ÕâλгæÓÑ×ö·¨»¹ÊÇÖµµÃÍÆ¼öµÄ£¬¾ÍÊÇ×Ô¼ºÅ¬Á¦ÁË£¬´ø×ÅÎÊÌâÓë´ó¼Ò̽ÌÖ¡£ µ«Äã²»¸ÃÐÄÍ´bb£¬µÃµ½ÖªÊ¶£¬¸¶³öÕæÊµµÄ½ðÇ®ÓÖÈçºÎ£¿ ÄãµÄÎÊÌâʵ»°Ëµ²»ÉÙ£¬Ö»Ö¸³ö½á¹¹£¬×Ô¼º·Òë°É 1¡¢associated with high-level estrogen exposureÐÞÊÎliver cyst growthºÍrequirement of interventions ½á¹¹£ºthis is based on both A and B 2¡¢a major approach has been to target cAMP production£ºhas beenÓ¦¸ÃÊÇbeµÄÏÖÔÚÍê³Éʱ£¬to¼°ÆäºóΪ²»¶¨Ê½£¬¿ÉÒÔÀí½âΪ±íÓï»òÕæÕýµÄÖ÷Óï¡£ 3¡¢whereÒýµ¼µÄÊǸö×´Óï´Ó¾ä¡£´Ë´Ó¾äÓÐ4¸öνÓï¡£ ½á¹¹£º.Thus,autocrine/paracrine loops are established where these factors νÓï1,2,3£¬4. 4¡¢given added weight¡°ÌåÏÖÁ˸ü¶àµÄÖØÒªÐÔ¡±»ò¡°Êܵ½Ô½À´Ô½¶àµÄÖØÊÓ¡± 5¡¢to achieve proper topology and folding of integral membrane or secreted glycoproteins in the endoplasmic reticulum (ER) ÊǸö¶¯´Ê²»¶¨Ê½½á¹¹£¬Óï·¨ÉÏÓ¦¸ÃÊÇ×öÄ¿µÄ×´Óï¡£Õû¾äΪ¼òµ¥¾ä£¬²»´æÔڴӾ䡣 the endoplasmic£¨ER)ÐÞÊεÄÓ¦¸ÃÊÇorºóÃæµÄ²¿·Ö¡£ 6¡¢potential factors£¬Ôõô·Òë×î±ê׼Ĩ£¿ ¸ù¾ÝÉÏÏÂÎÄÒë°¡£¬Ëƺõ¿ÉΪ¡°Ç±ÔÚÒò×Ó¡±»ò¡°¿ÉÄܵÄÒò×Ó¡±»ò¡°¿ÉÄÜÒòËØ¡± ×îºóÒ»¾äÒ²²»¶®£¬¼´ stimulatesÖÁ×îºó£¬¸Ð¾õ²»Í¨ÄØ£¿ stimulates×öSecretinµÄνÓstimulatesºóÊDZöÓ¼òµ¥½á¹¹£¬¸ù¾ÝÒâ˼°´ººÓï׼ȷ±í´ï¾ÍÊÇÁË |
3Â¥2011-06-04 22:20:58













»Ø¸´´ËÂ¥